Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy

Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon‐alpha (PEG‐IFN‐alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony‐stimulating factor (G‐CSF) supplement. We analysed the database of patients who completed treat...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of viral hepatitis Vol. 14; no. 11; pp. 782 - 787
Main Authors:	Koirala, J., Gandotra, S. D., Rao, S., Sangwan, G., Mushtaq, A., Htwe, T. H., Adamski, A., Blessman, D., Khardori, N. M.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-11-2007
Subjects:	Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Drug Therapy, Combination Female granulocyte colony-stimulating factor Granulocyte Colony-Stimulating Factor - administration & dosage Hepacivirus - growth & development hepatitis C Hepatitis C virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Leukocyte Count Logistic Models Male Middle Aged neutropenia Neutropenia - chemically induced Neutropenia - drug therapy pegylated interferon-alpha Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins Ribavirin - administration & dosage Ribavirin - therapeutic use Time Factors Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Many patients with chronic hepatitis C (HCV) infection undergoing treatment with pegylated interferon‐alpha (PEG‐IFN‐alpha) and ribavirin develop neutropenia requiring dose reduction or granulocyte colony‐stimulating factor (G‐CSF) supplement. We analysed the database of patients who completed treatment for chronic HCV infection between 2003 and 2006. Patients with absolute neutrophil counts below 1000 cells/μL were initiated on G‐CSF (G‐CSF group) while a matching group of patients who received anti‐HCV treatment without developing neutropenia were used as a control group (non‐G‐CSF group). Patients on the G‐CSF arm were divided into two subgroups based on the timing of G‐CSF administration relative to PEG‐IFN‐alpha administration. Of the 163 patients with HCV infection, 30 patients received G‐CSF, most of who were maintained on 300 μg of G‐CSF once a week. Administration of G‐CSF 2 days before or after each dose of PEG‐IFN‐alpha did not make a significant difference in the neutrophil counts. In the G‐CSF arm, 23 of 30 patients (77%) had undetectable end‐of‐treatment viral response which was comparable with 27 of 30 in the control group (90%; P = 0.17). There was no statistically significant difference in the sustained viral response between the two groups (61%vs 76%, P = 0.18). In most patients PEG‐IFN‐alpha induced neutropenia improved with a once‐a‐week dose of G‐CSF with a comparable virological outcome. Timing of G‐CSF administration did not make any significant impact on the patient's neutrophil counts but was better tolerated when given 2 days apart from PEG‐IFN‐alpha.
Bibliography:	ArticleID:JVH870 Presented at the 44th Annual Meeting of Infectious Disease Society of America (IDSA), Toronto, Canada, 12-15 October 2006. istex:99533B0065780DD3BA1C4C251A6218E2C9A562B1 ark:/67375/WNG-XVVPTLWH-8 Presented at the 44th Annual Meeting of Infectious Disease Society of America (IDSA), Toronto, Canada, 12–15 October 2006. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1352-0504 1365-2893
DOI:	10.1111/j.1365-2893.2007.00870.x